ClinicalTrials.gg
Not yet recruitingNCT07942415Updated Nov 17, 2026

Stress Levels Periodontitis and Metabolic Syndrome

An observational study in Periodontitis, Metabolic Syndrome (MetS) and Stress, sponsored by Recep Tayyip Erdogan University Training and Research Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Recep Tayyip Erdogan University Training and Research Hospital · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Periodontitis by Recep Tayyip Erdogan University Training and Research Hospital — 8 open to participants now, 8 under way, none of them phase 3. Periodontitis · Recep Tayyip Erdogan University Training and Research Hospital.

Planned enrollment
Largest of 11
100 · median 100
Started
2026
with 4 others
Observational
11 of 12
7 open now
Registered
12th of 12
by date

Among the 12 studies in Periodontitis by Recep Tayyip Erdogan University Training and Research Hospital, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2026, is one of 11 observational ones, and was the 12th registered.

Periodontitis

1,235 studies on the registry are indexed under Periodontitis; 298 are open to participants now.

Browse Periodontitis studies →

Open to participants now

8 of the 12 studies in Periodontitis by Recep Tayyip Erdogan University Training and Research Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 160 Periodontitis studies recruiting now, 79 (49%) set no upper age limit and 60 (38%) stop at 75 or younger; 12 take children under 18; 77 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Periodontitis by Recep Tayyip Erdogan University Training and Research Hospital, or all of them as a file.
02

Study summary

The purpose of this observational study is to evaluate the levels of salivary cortisol, dehydroepiandrosterone, and chromogranin A, as well as the levels of psychological stress, in patients with periodontitis and/or metabolic syndrome. The primary research question the study aims to address is:

- Are the levels of salivary cortisol, dehydroepiandrosterone, and chromogranin A and psychological stress in patients with periodontitis and/or metabolic syndrome associated with their periodontal status and metabolic syndrome?

Participants-categorized into a control group, those with periodontitis only, those with metabolic syndrome only, and those with both periodontitis and metabolic syndrome-will undergo a clinical periodontal examination, provide saliva samples for the assessment of cortisol, dehydroepiandrosterone, and chromogranin A levels, and complete validated scales designed to measure psychological stress. The findings will help clarify the relationship between psychological stress, stress-related salivary biomarkers, metabolic syndrome, and periodontal health.

Read the detailed description

Within the scope of the study, the Rosenberg Self-Esteem Scale and the Social Appearance Anxiety Scale will be administered. Salivary markers-cortisol, dehydroepiandrosterone, and chromogranin A-will be analyzed using the ELISA method. Periodontal clinical parameters (plaque index, gingival index, bleeding on probing, probing pocket depth, and clinical attachment loss) will be measured.

03

Conditions studied

  • Periodontitis
  • Metabolic Syndrome (MetS)
  • Stress
  • Cortisol
  • Dehydroepiandrosterone

Keywords

  • periodontitis
  • Metabolic Syndrome (MetS)
  • Stress
  • cortisol
  • dehydroepiandrosterone
  • chromogranin A
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Individuals who presented to the Internal Medicine Outpatient Clinic at the Recep Tayyip Erdoğan University Faculty of Medicine Training and Research Hospital and met the diagnostic criteria for metabolic syndrome as defined by the American Diabetes Association (ADA) or the International Diabetes Federation (IDF); healthy volunteers who presented to the Periodontology Clinic at the Recep Tayyip Erdoğan University Faculty of Dentistry; and individuals who were diagnosed with periodontitis but did not meet the criteria for metabolic syndrome.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals between the ages of 18 and 65,
  • Those who have at least 20 natural teeth,
  • Individuals who have provided written for participation in the research
  • Individuals diagnosed with periodontitis and/or metabolic syndrome

Exclusion criteria

Exclusion Criteria:

  • Individuals who have received periodontal treatment (surgical or non-surgical) within the last 6 months,
  • Individuals with a history of using antibiotics, anti-inflammatory drugs, or medications within the last 3 months,
  • Individuals with a history of systemic disease who do not meet the criteria for metabolic syndrome (e.g., , diseases, liver/kidney failure),
  • Individuals who have been diagnosed with a psychiatric disorder or are undergoing regular psychiatric treatment,
  • Pregnant or breastfeeding women,
  • Individuals with physical or mental disabilities that prevent them from maintaining their oral hygiene.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Healthy Control Group

    Individuals with no clinical or radiographic signs of periodontal disease and no history of systemic disease

  • Periodontitis Group (Systemically Healthy)

    Individuals diagnosed with periodontitis according to the 2018 American Academy of Periodontology classification, but with no history of systemic disease

  • Metabolic Syndrome Group (Periodontally Healthy)

    Individuals diagnosed with metabolic syndrome according to American Diabetes Association or International Diabetes Federation criteria, but without periodontitis

  • Periodontitis + Metabolic Syndrome Group

    Individuals diagnosed with both metabolic syndrome and periodontitis

06

What researchers measure

Primary outcomes

  1. Plaque Index

    Plaque Index (PI) (Silness and Löe, 1964) This index is used to evaluate the amount of dental plaque accumulation on tooth surfaces. Each tooth's four surfaces (buccal, lingual, mesial, distal) are examined using a probe or visually. Each surface is scored from 0 to 3. The average score is calculated for each tooth. The overall plaque index is obtained by averaging the scores from all examined teeth. Score Description 0 No plaque. 1. No visible plaque, but a slight film of plaque is detected when a probe is run along the gingival margin. 2. Visible plaque along the gingival margin, forming a continuous band. 3. Abundant plaque covering the gingival area and extending toward the middle of the tooth surface, including the interproximal spaces.

    Time frame: Day 1

  2. Gingival Index

    The Gingival Index is used to assess the presence and severity of gingival inflammation (gingivitis). Four surfaces of each tooth (buccal, lingual, mesial, distal) are examined visually and with a periodontal probe. The evaluation considers color changes, edema (swelling), tissue consistency, and bleeding on probing. Each surface is scored from 0 to 3. The average score per tooth is calculated, and then the overall average is used to determine the individual's GI score. Score Description 0 Healthy gingiva: normal color and texture, no bleeding 1. Mild inflammation: slight color change and swelling, no bleeding on probing 2. Moderate inflammation: redness, edema, soft tissue, bleeding on probing 3. Severe inflammation: marked redness and swelling, ulceration, possible spontaneous bleeding

    Time frame: Day 1

  3. Bleeding on Probing Index

    This index is used to assess the presence and severity of gingival inflammation by observing bleeding after gentle pressure is applied to the gingival sulcus using a periodontal probe. A thin periodontal probe is gently inserted into the gingival sulcus with light pressure (approximately 20-25 grams). Bleeding occurring within 10-30 seconds is observed. Each measurement site is recorded as either "bleeding present" or "bleeding absent." Presence of bleeding is an early and sensitive indicator of gingival inflammation. Score Description: 0 No bleeding 1 Bleeding present (mild or severe)

    Time frame: Day 1

  4. Probing Pocket Depth

    Using a Williams periodontal probe, the distance between the gingival margin and the base of the periodontal pocket is measured in millimeters at six sites per tooth: mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual. All teeth are measured. The values obtained from each site are summed and then divided by the total number of sites measured. This gives the average probing depth for the individual. Measurement Interpretation 1-3 mm Healthy sulcus 4-5 mm Shallow to moderate pocket ≥6 mm Deep periodontal pocket (advanced disease)

    Time frame: Day 1

  5. Clinical Attachment Loss

    Using a Williams periodontal probe, the distance between the enamel-cementum junction and the base of the periodontal pocket is measured in millimeters at six sites per tooth: mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual. All teeth are measured. The values obtained from each site are summed and then divided by the total number of sites measured. This gives the average probing depth for the individual. Clinical Attachment Loss Value Interpretation 0-1 mm Healthy / minimal loss 2-3 mm Mild attachment loss 4-5 mm Moderate attachment loss ≥6 mm Severe attachment loss

    Time frame: Day 1

  6. Collection of Saliva Samples

    Prior to saliva collection, participants will be instructed to abstain from caffeine and/or nicotine for at least 4 hours and alcohol for at least 24 hours. Saliva will be collected between 9:00 AM and 11:00 AM to minimize circadian variations. Unstimulated saliva flow rate will be collected over 10 minutes using the spitting method and will be expressed in mL/min.

    Time frame: Day 2

Secondary outcomes

  1. Rosenberg Self-Esteem Scale Score

    A four-point scale will be used to score responses to the 10 items. Positive questions are scored as 3: Strongly agree; 2: Agree; 1: Disagree; and 0: Strongly disagree, while negative questions are scored as 0: Strongly agree; 1: Agree; 2: Disagree; and 3: Strongly disagree. According to the final total score of the Rosenberg Self-Esteem Scale scores between 0-15, 15-25, and 25-30 indicate low, normal, and high self-esteem levels, respectively.

    Time frame: Day 1

  2. Social Appearance Anxiety Scale Score

    Social Appearance Anxiety Scale 16-item scale concerns how patients feel about their appearance. A score of 1 to 5 is given for each item as follows: 1, completely disagree; 2, partially disagree; 3, unsure; 4, partially agree; 5, I completely agree. Scores range from 16 to 80, with higher scores representing greater social appearance anxiety.

    Time frame: Day 1

  3. Concentration of Cortisol, Dehydroepiandrosterone and Chromogranin A

    Salivary cortisol, Dehydroepiandrosterone and Chromogranin A will be obtained from unstimulated whole saliva samples. Saliva samples will be stored at -20°C until analyzed. Human salivary cortisol, Dehydroepiandrosterone, and Chromogranin A will be measured using radioenzyme immunoassay using a commercial enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions.

    Time frame: approximately in the 4th month

07

Study locations

1 site
  • Department of Periodontology of the Faculty of Dentistry of Recep Tayyip Erdogan University
    Rize, Rize Province 53020, Turkey (Türkiye)
    • RTEU Faculty of Dentistry, Department of Periodontology · Contactdis@erdogan.edu.tr · +90 464 222 00 00
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2027, 3 months later.

Of 85 non-industry observational studies under Periodontitis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 3 months is below that.

Counting every sponsor, half of 86 studies reached it within 13 months; a quarter within 7 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Mar 15, 2027
CompletionEst.
Apr 19, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07942415
Lead sponsor
Recep Tayyip Erdogan University Training and Research Hospital
Responsible party
Dilek KARADOĞAN (Prof. Dr., Recep Tayyip Erdogan University Training and Research Hospital) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Mar 15, 2027 (estimated)
Completion
Apr 19, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Oguz KOSE, Professor Dr.
Contact
oguz.kose@erdogan.edu.tr
+90 541 348 64 65

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion